Target Corporation to Webcast 3rd Quarter Earnings Conference Call on Wednesday, November 16, 2016
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Harry and Meghan surprised by King Charles' letter on their status
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Qualcomm to issue warrant to Amazon for up to 25M shares
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
UBS Remains Sidelined on Target (TGT) Following 3Q - PT to $78
November 17, 2016 10:11 AM ESTUBS reiterated a Neutral rating on Target (NYSE: TGT), and raised the price target to $78.00 (from $72.00), following the company's 3Q earnings report. While the retail backdrop remains challenging, UBS thinks that TGT's -1% to 1% 4Q comp guidance is achievable. It seems to have a competitive product lineup for the holidays. The 10% off promo it ran in Aug. provided a chance to test its systems in... More
Jefferies Remains Sidelined on Target (TGT) Following 3Q - PT to $75
November 17, 2016 8:36 AM ESTJefferies reiterated a Hold rating on Target (NYSE: TGT), and raised the price target to $75.00 (from $72.00), following the company's 3Q earnings report. Electronics & entertainment underperformed, but Q3 improved with new product introductions. Pharmacy scripts in the CVS business at Target continue to run below... More
